Therapeutic potential of tocotrienols as chemosensitizers in cancer therapy.
cancer
chemoresistance
chemosensitization
combination therapy
phytochemicals
tocotrienol
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
revised:
29
12
2023
received:
31
08
2023
accepted:
15
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
Chemoresistance is the adaptation of cancer cells against therapeutic agents. When exhibited by cancer cells, chemoresistance helps them to avoid apoptosis, cause relapse, and metastasize, making it challenging for chemotherapeutic agents to treat cancer. Various strategies like dosage modification of drugs, nanoparticle-based delivery of chemotherapeutics, antibody-drug conjugates, and so on are being used to target and reverse chemoresistance, one among such is combination therapy. It uses the combination of two or more therapeutic agents to reverse multidrug resistance and improve the effects of chemotherapy. Phytochemicals are known to exhibit chemosensitizing properties and are found to be effective against various cancers. Tocotrienols (T3) and tocopherols (T) are natural bioactive analogs of vitamin E, which exhibit important medicinal value and potential curative properties apart from serving as an antioxidant and nutrient supplement. Notably, T3 exhibits a variety of pharmacological activities like anticancer, anti-inflammatory, antiproliferative, and so on. The chemosensitizing property of tocotrienol is exhibited by modulating several signaling pathways and molecular targets involved in cancer cell survival, proliferation, invasion, migration, and metastasis like NF-κB, STATs, Akt/mTOR, Bax/Bcl-2, Wnt/β-catenin, and many more. T3 sensitizes cancer cells to chemotherapeutic drugs including cisplatin, doxorubicin, and paclitaxel increasing drug concentration and cytotoxicity. Discussed herewith are the chemosensitizing properties of tocotrienols on various cancer cell types when combined with various drugs and biological molecules.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Biotechnology (DBT), Government of India
ID : BT/556/NE/U-Excel/2016
Organisme : Science and Engineering Research Board (SERB)-National Post-Doctoral Fellowship (N-PDF)
ID : PDF/2021/004053
Organisme : DST-INSPIRE
Informations de copyright
© 2024 John Wiley & Sons, Ltd.
Références
Abdul Rahman, A., Jamal, A. R., Harun, R., Mohd Mokhtar, N., & Wan Ngah, W. Z. (2014). Gamma-tocotrienol and hydroxy-chavicol synergistically inhibits growth and induces apoptosis of human glioma cells. BMC Complementary and Alternative Medicine, 14, 213. https://doi.org/10.1186/1472-6882-14-213
Abubakar, I. B., Lim, K. H., Kam, T. S., & Loh, H. S. (2016). Synergistic cytotoxic effects of combined delta-tocotrienol and jerantinine B on human brain and colon cancers. Journal of Ethnopharmacology, 184, 107-118. https://doi.org/10.1016/j.jep.2016.03.004
Abubakar, I. B., Lim, K. H., Kam, T. S., & Loh, H. S. (2017). Enhancement of apoptotic activities on brain cancer cells via the combination of gamma-tocotrienol and jerantinine A. Phytomedicine, 30, 74-84. https://doi.org/10.1016/j.phymed.2017.03.004
Abubakar, I. B., Lim, K.-H., Kam, T.-S., & Loh, H.-S. (2018). Jerantinine B enhances the mitochondria-mediated apoptosis by p53 activation in human glioblastoma cells via a combination with δ-tocotrienol. Journal of Biologically Active Products from Nature, 8(1), 21-27. https://doi.org/10.1080/22311866.2018.1440253
Abu-Fayyad, A., & Nazzal, S. (2017). Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity. International Journal of Pharmaceutics, 528(1-2), 463-470. https://doi.org/10.1016/j.ijpharm.2017.06.031
Aggarwal, B. B., Sundaram, C., Prasad, S., & Kannappan, R. (2010). Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases. Biochemical Pharmacology, 80(11), 1613-1631. https://doi.org/10.1016/j.bcp.2010.07.043
Aggarwal, V., Kashyap, D., Sak, K., Tuli, H. S., Jain, A., Chaudhary, A., Garg, V. K., Sethi, G., & Yerer, M. B. (2019). Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. International Journal of Molecular Sciences, 20(3), 656. https://doi.org/10.3390/ijms20030656
Ahmed, R. A., Alawin, O. A., & Sylvester, P. W. (2016). gamma-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling. Cell Proliferation, 49(4), 460-470. https://doi.org/10.1111/cpr.12270
Ahmed, S. A., Parama, D., Daimari, E., Girisa, S., Banik, K., Harsha, C., Dutta, U., & Kunnumakkara, A. B. (2021). Rationalizing the therapeutic potential of apigenin against cancer. Life Science, 267, 118814.
Ahn, K. S., Sethi, G., Krishnan, K., & Aggarwal, B. B. (2007). Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. Journal of Biological Chemistry, 282(1), 809-820. https://doi.org/10.1074/jbc.M610028200
Ahsan, H., Ahad, A., Iqbal, J., & Siddiqui, W. A. (2014). Pharmacological potential of tocotrienols: A review. Nutrition & Metabolism (London), 11(1), 52. https://doi.org/10.1186/1743-7075-11-52
Akl, M. R., Ayoub, N. M., Abuasal, B. S., Kaddoumi, A., & Sylvester, P. W. (2013). Sesamin synergistically potentiates the anticancer effects of gamma-tocotrienol in mammary cancer cell lines. Fitoterapia, 84, 347-359. https://doi.org/10.1016/j.fitote.2012.12.013
Akl, M. R., Ayoub, N. M., & Sylvester, P. W. (2012). Mechanisms mediating the synergistic anticancer effects of combined gamma-tocotrienol and sesamin treatment. Planta Medica, 78(16), 1731-1739. https://doi.org/10.1055/s-0032-1315302
Alayoubi, A. Y., Anderson, J. F., Satyanarayanajois, S. D., Sylvester, P. W., & Nazzal, S. (2013). Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells. European Journal of Pharmaceutical Sciences, 48(3), 385-392. https://doi.org/10.1016/j.ejps.2012.12.011
Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin and cancer: An “old-age” disease with an “age-old” solution. Cancer Letters, 267(1), 133-164. https://doi.org/10.1016/j.canlet.2008.03.025
Andreyev, H. J. N., Matthews, J., Adams, C., Gothard, L., Lucy, C., Tovey, H., Boyle, S., Anbalagan, S., Musallam, A., Yarnold, J., Abraham, D., Bliss, J., Abdi, B. A., Taylor, A., & Hauer-Jensen, M. (2022). Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study. Radiotherapy and Oncology, 168, 130-137.
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2020). Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1873(1), 188314. https://doi.org/10.1016/j.bbcan.2019.188314
Asay, S., Graham, A., Hollingsworth, S., Barnes, B., Oblad, R. V., Michaelis, D. J., & Kenealey, J. D. (2020). gamma-tocotrienol and alpha-tocopherol ether acetate enhance docetaxel activity in drug-resistant prostate cancer cells. Molecules, 25(2), 398. https://doi.org/10.3390/molecules25020398
Aswathy, M., Banik, K., Parama, D., Sasikumar, P., Harsha, C., Joseph, A. G., Sherin, D. R., Thanathu, M. K., Kunnumakkara, A. B. & Vasu R. K. (2021). Exploring the cytotoxic effects of the extracts and bioactive triterpenoids from Dillenia indica against Oral squamous cell carcinoma: A scientific interpretation and validation of indigenous knowledge. ACS Pharmacology & Translational Science, 4(2), 834-847. https://doi.org/10.1021/acsptsci.1c00011
Aumeeruddy, M. Z., & Mahomoodally, M. F. (2019). Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone. Cancer, 125(10), 1600-1611. https://doi.org/10.1002/cncr.32022
Ayoub, N. M., Akl, M. R., & Sylvester, P. W. (2013). Combined gamma-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration. Cell Proliferation, 46(5), 538-553. https://doi.org/10.1111/cpr.12059
Ayoub, N. M., Bachawal, S. V., & Sylvester, P. W. (2011). gamma-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Proliferation, 44(6), 516-526. https://doi.org/10.1111/j.1365-2184.2011.00785.x
Baba, A. I., & Câtoi, C. (2007). Comparative oncology. Publishing House of the Romanian Academy Bucharest.
Babu, B. H., Jayram, H. N., Nair, M. G., Ajaikumar, K. B., & Padikkala, J. (2003). Free radical scavenging, antitumor and anticarcinogenic activity of gossypin. Journal of Experimental & Clinical Cancer Research, 22(4), 581-589.
Bachawal, S. V., Wali, V. B., & Sylvester, P. W. (2010a). Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Research, 30(2), 429-437.
Bachawal, S. V., Wali, V. B., & Sylvester, P. W. (2010b). Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer, 10, 84. https://doi.org/10.1186/1471-2407-10-84
Baldi, A., De Luca, A., Maiorano, P., D'Angelo, C., & Giordano, A. (2020). Curcumin as an anticancer agent in malignant mesothelioma: A review. International Journal of Molecular Sciences, 21(5), 1839. https://doi.org/10.3390/ijms21051839
Banik, K., Khatoon, E., Harsha, C., Rana, V., Parama, D., Thakur, K. K., Bishayee, A., & Kunnumakkara, A. B. (2022). Wogonin and its analogs for the prevention and treatment of cancer: A systematic review. Phytotherapy Research, 36(5), 1854-1883. https://doi.org/10.1002/ptr.7386
Banik, K., Khatoon, E., Hegde, M., Thakur, K. K., Puppala, E. R., Naidu, V. G. M., & Kunnumakkara, A. B. (2021). A novel bioavailable curcumin-galactomannan complex modulates the genes responsible for the development of chronic diseases in mice: A RNA sequence analysis. Life Science, 287, 120074. https://doi.org/10.1016/j.lfs.2021.120074
Banik, K., Ranaware, A. M., Deshpande, V., Nalawade, S. P., Padmavathi, G., Bordoloi, D., Sailo, B. L., Shanmugam, M. K., Fan, L., Arfuso, F., Sethi, G., & Kunnumakkara, A. B. (2019). Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacological Research, 144, 192-209. https://doi.org/10.1016/j.phrs.2019.04.004
Banik, K., Ranaware, A. M., Harsha, C., Nitesh, T., Girisa, S., Deshpande, V., Fan L., Nalawade S. P., Sethi G., & Kunnumakkara, A. B. (2020). Piceatannol: A natural stilbene for the prevention and treatment of cancer. Pharmacological Research, 153, 104635. https://doi.org/10.1016/j.phrs.2020.104635
Bayat Mokhtari, R., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. Oncotarget, 8(23), 38022-38043. https://doi.org/10.18632/oncotarget.16723
Bhattacharya, T., Dutta, S., Akter, R., Rahman, M. H., Karthika, C., Nagaswarupa, H. P., Murthy, H. C. A., Fratila, O., Brata, R., & Bungau, S. (2021). Role of phytonutrients in nutrigenetics and nutrigenomics perspective in curing breast cancer. Biomolecules, 11(8), 1176. https://doi.org/10.3390/biom11081176
Bordoloi, D., & Kunnumakkara, A. B. (2018). The potential of curcumin: A multitargeting agent in cancer cell chemosensitization. In Role of nutraceuticals in cancer chemosensitization (pp. 31-60). Elsevier.
Bordoloi, D., Monisha, J., Roy, N. K., Padmavathi, G., Banik, K., Harsha, C., Wang, H., Kumar, A. P., Arfuso, F., & Kunnumakkara, A. B. (2019). An investigation on the therapeutic potential of butein, a Tretrahydroxychalcone against human oral squamous cell carcinoma. Asian Pacific Journal of Cancer Prevention, 20(11), 3437-3446. https://doi.org/10.31557/APJCP.2019.20.11.3437
Bordoloi, D., Roy, N. K., Monisha, J., Padmavathi, G., & Kunnumakkara, A. B. (2016). Multi-targeted agents in cancer cell chemosensitization: What we learnt from curcumin thus far. Recent Patents on Anti-Cancer Drug Discovery, 11(1), 67-97. https://doi.org/10.2174/1574892810666151020101706
Boyd, N. H., Tran, A. N., Bernstock, J. D., Etminan, T., Jones, A. B., Gillespie, G. Y., Friedman, G. K., & Hjelmeland, A. B. (2021). Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics, 11(2), 665-683. https://doi.org/10.7150/thno.41692
Buhrmann, C., Kunnumakkara, A. B., Popper, B., Majeed, M., Aggarwal, B. B., & Shakibaei, M. (2020). Calebin a potentiates the effect of 5-FU and TNF-beta (Lymphotoxin alpha) against human colorectal cancer cells: Potential role of NF-kappaB. International Journal of Molecular Sciences, 21(7), 2393. https://doi.org/10.3390/ijms21072393
Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. International Journal of Molecular Sciences, 21(9), 3233. https://doi.org/10.3390/ijms21093233
Cardenas, E., & Ghosh, R. (2013). Vitamin E: A dark horse at the crossroad of cancer management. Biochemical Pharmacology, 86(7), 845-852. https://doi.org/10.1016/j.bcp.2013.07.018
Chan, D., Meister, M. L., Madhani, C. R., Elfakhani, M., Yount, S. T., Ji, X., Feresin, R. G., Wanders, D., & Mo, H. (2021). Synergistic impact of xanthorrhizol and d-delta-tocotrienol on the proliferation of murine B16 melanoma cells and human DU145 prostate carcinoma cells. Nutrition and Cancer, 73(9), 1746-1757. https://doi.org/10.1080/01635581.2020.1807573
Chang, P. N., Yap, W. N., Wing Lee, D. T., Ling, M., Wong, Y. C., & Yap, Y. L. (2009). Evidence of γ-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutrition and Cancer, 61(3), 357-366.
Chavda, V., Patel, V., Yadav, D., Shah, J., Patel, S., & Jin, J. O. (2020). Therapeutics and research related to glioblastoma: Advancements and future targets. Current Drug Metabolism, 21(3), 186-198. https://doi.org/10.2174/1389200221666200408083950
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Letters, 370(1), 153-164. https://doi.org/10.1016/j.canlet.2015.10.010
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., van den Broek, M., Beisel, C., Stadler, M. B., Gedye, C., Reis, B., Pe'er, D., & Bodenmiller, B. (2017). An immune atlas of clear cell renal cell carcinoma. Cell, 169(4), 736-749 e718. https://doi.org/10.1016/j.cell.2017.04.016
Chin, S. F., Hamid, N. A., Latiff, A. A., Zakaria, Z., Mazlan, M., Yusof, Y. A., Karim, A. A., Ibahim, J., Hamid, Z., & Ngah, W. Z. (2008). Reduction of DNA damage in older healthy adults by Tri E Tocotrienol supplementation. Nutrition, 24(1), 1-10. https://doi.org/10.1016/j.nut.2007.08.006
Chinembiri, T. N., du Plessis, L. H., Gerber, M., Hamman, J. H., & du Plessis, J. (2014). Review of natural compounds for potential skin cancer treatment. Molecules, 19(8), 11679-11721. https://doi.org/10.3390/molecules190811679
Choi, Y. H., & Yu, A. M. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Current Pharmaceutical Design, 20(5), 793-807. https://doi.org/10.2174/138161282005140214165212
Choudhary, H., Bordoloi, D., Prakash, J., Manteghi, N., Padmavathi, G., Monisha, J., & Kunnumakkara, A. B. (2018). Different chemosensitization approaches in gastric cancer. Cancer Cell Chemoresist Chemosensit, 267-319.
Collins, L. G., Haines, C., Perkel, R., & Enck, R. E. (2007). Lung cancer: Diagnosis and management. American Family Physician, 75(1), 56-63.
Comitato, R., Guantario, B., Leoni, G., Nesaretnam, K., Ronci, M. B., Canali, R., & Virgili, F. (2016). Tocotrienols induce endoplasmic reticulum stress and apoptosis in cervical cancer cells. Genes & Nutrition, 11, 32. https://doi.org/10.1186/s12263-016-0543-1
Constantinou, C., Charalambous, C., & Kanakis, D. (2020). Vitamin E and cancer: An update on the emerging role of gamma and delta tocotrienols. European Journal of Nutrition, 59(3), 845-857. https://doi.org/10.1007/s00394-019-01962-1
Conteduca, V., Ku, S. Y., Fernandez, L., Dago-Rodriquez, A., Lee, J., Jendrisak, A., Slade, M., Gilbertson, C., Manohar, J., Sigouros, M., Wang, Y., Dittamore, R., Wenstrup, R., Mosquera, J. M., Schonhoft, J. D., & Beltran, H. (2021). Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precision Oncology, 5(1), 76. https://doi.org/10.1038/s41698-021-00211-1
Crucitta, S., Cucchiara, F., Mathijssen, R., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R., Danesi, R., & Del Re, M. (2022). Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 104, 102340. https://doi.org/10.1016/j.ctrv.2022.102340
Dagogo-Jack, I., & Shaw, A. T. (2018). Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology, 15(2), 81-94. https://doi.org/10.1038/nrclinonc.2017.166
Daimary, U. D., Parama, D., Rana, V., Banik, K., Kumar, A., Harsha, C., & Kunnumakkara, A. B. (2021). Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases. Current Research in Pharmacology and Drug Discovery, 2, 100008. https://doi.org/10.1016/j.crphar.2020.100008
Dalloul, A. (2013). Hypoxia and visualization of the stem cell niche. Methods in Molecular Biology, 1035, 199-205. https://doi.org/10.1007/978-1-62703-508-8_17
Damia, G., & D'Incalci, M. (2007). Targeting DNA repair as a promising approach in cancer therapy. European Journal of Cancer, 43(12), 1791-1801. https://doi.org/10.1016/j.ejca.2007.05.003
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019). Colorectal cancer. Lancet, 394(10207), 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Dentro, S. C., Leshchiner, I., Haase, K., Tarabichi, M., Wintersinger, J., Deshwar, A. G., Yu, K., Rubanova, Y., Macintyre, G., Demeulemeester, J., & Vázquez-García, I. (2021). Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 184(8), 2239-2254.e2239. https://doi.org/10.1016/j.cell.2021.03.009
Devi Daimary, U., Girisa, S., Parama, D., Verma, E., Kumar, A., & Kunnumakkara, A. B. (2022). Embelin: A novel XIAP inhibitor for the prevention and treatment of chronic diseases. Journal of Biochemical and Molecular Toxicology, 36(2), e22950. https://doi.org/10.1002/jbt.22950
Eitsuka, T., Tatewaki, N., Nishida, H., Kurata, T., Nakagawa, K., & Miyazawa, T. (2014). Synergistic inhibition of cancer cell proliferation with a combination of delta-tocotrienol and ferulic acid. Biochemical and Biophysical Research Communications, 453(3), 606-611. https://doi.org/10.1016/j.bbrc.2014.09.126
Eitsuka, T., Tatewaki, N., Nishida, H., Nakagawa, K., & Miyazawa, T. (2016). A combination of delta-tocotrienol and ferulic acid synergistically inhibits telomerase activity in DLD-1 human colorectal adenocarcinoma cells. Journal of Nutritional Science and Vitaminology (Tokyo), 62(5), 281-287. https://doi.org/10.3177/jnsv.62.281
EEl-Senduny, F. F., Altouhamy, M., Zayed, G., Harsha, C., Jalaja, R., Somappa, S. B., Nair, M. S., Kunnumakkara, A. B., Alsharif, F. M., & Badria, F. A. (2021). Azadiradione-loaded liposomes with improved bioavailability and anticancer efficacy against triple negative breast cancer. Journal of Drug Delivery Science and Technology, 65, 102665.
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., Mitra, S., Dhama, K., Habiballah, M. M., Haque, S., Islam, A., & Hassan, M. M. (2022). Multidrug resistance in cancer: Understanding molecular mechanisms, Immunoprevention and Therapeutic Approaches. Frontiers in Oncology, 12, 891652. https://doi.org/10.3389/fonc.2022.891652
Farhana, L., Sarkar, S., NangiaMakker, P., Yu, Y., Khosla, P., Levi, E., Azmi, A., & Majumdar, A. P. N. (2020). Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice. PLoS One, 15(3), e0229823. https://doi.org/10.1371/journal.pone.0229823
Farina, N., Llewellyn, D., Isaac, M. G., & Tabet, N. (2017). Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews, 1(1), CD002854. https://doi.org/10.1002/14651858.CD002854.pub4
Fernandes, N. V., Guntipalli, P. K., & Mo, H. (2010). d-delta-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells. Anticancer Research, 30(12), 4937-4944.
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010). ABC transporters in cancer: More than just drug efflux pumps. Nature Reviews Cancer, 10(2), 147-156. https://doi.org/10.1038/nrc2789
Fontana, F., Anselmi, M., & Limonta, P. (2022). Exploiting the metabolic consequences of PTEN loss and Akt/hexokinase 2 hyperactivation in prostate cancer: A new role for delta-tocotrienol. International Journal of Molecular Sciences, 23(9), 5269. https://doi.org/10.3390/ijms23095269
Fontana, F., Marzagalli, M., Raimondi, M., Zuco, V., Zaffaroni, N., & Limonta, P. (2021). delta-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis. Cell Proliferation, 54(11), e13111. https://doi.org/10.1111/cpr.13111
Francois, R. A., Zhang, A., Husain, K., Wang, C., Hutchinson, S., Kongnyuy, M., Batra, S. K., Coppola, D., Sebti, S. M., & Malafa, M. P. (2019). Vitamin E delta-tocotrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP(s). Cancer Cell International, 19, 189. https://doi.org/10.1186/s12935-019-0876-0
Gastaldi, S., Comoglio, P. M., & Trusolino, L. (2010). The Met oncogene and basal-like breast cancer: Another culprit to watch out for? Breast Cancer Research, 12(4), 208. https://doi.org/10.1186/bcr2617
Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021). Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer. Molecular Biomedicine, 2(1), 21. https://doi.org/10.1186/s43556-021-00035-2
Girisa, S., Saikia, Q., Bordoloi, D., Banik, K., Monisha, J., Daimary, U. D., Verma, E., Ahn, K. S., & Kunnumakkara, A. B. (2021). Xanthohumol from Hop: Hope for cancer prevention and treatment. IUBMB Life, 73(8), 1016-1044. https://doi.org/10.1002/iub.2522
Gopalan, A., Yu, W., Sanders, B. G., & Kline, K. (2013). Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Letters, 328(2), 285-296. https://doi.org/10.1016/j.canlet.2012.10.003
Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual Review of Medicine, 53, 615-627. https://doi.org/10.1146/annurev.med.53.082901.103929
Guestini, F., McNamara, K. M., & Sasano, H. (2017). The use of chemosensitizers to enhance the response to conventional therapy in triple-negative breast cancer patients. Future Medicine, 6, 127-131.
Guthrie, N., Gapor, A., Chambers, A. F., & Carroll, K. K. (1997). Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. Journal of Nutrition, 127(3), 544S-548S. https://doi.org/10.1093/jn/127.3.544S
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023). Curcumin formulations for better bioavailability: What we learned from clinical trials thus far? ACS Omega, 8(12), 10713-10746. https://doi.org/10.1021/acsomega.2c07326
Hegde, M., Girisa, S., Naliyadhara, N., Kumar, A., Alqahtani, M. S., Abbas, M., Mohan, C. D., Warrier, S., Hui, K. M., Rangappa, K. S., Sethi, G., & Kunnumakkara, A. B. (2022). Natural compounds targeting nuclear receptors for effective cancer therapy. Cancer and Metastasis Reviews, 42, 765-822. https://doi.org/10.1007/s10555-022-10068-w
Hegde, M., Naliyadhara, N., Unnikrishnan, J., Alqahtani, M. S., Abbas, M., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2023). Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives. Cancer Letters, 556, 216066. https://doi.org/10.1016/j.canlet.2023.216066
Ho, D. W., Tsui, Y. M., Chan, L. K., Sze, K. M., Zhang, X., Cheu, J. W., Chiu, Y. T., Lee, J. M., Chan, A. C., Cheung, E. T., Yau, D. T., Chia, N. H., Lo, I. L., Sham, P. C., Cheung, T. T., Wong, C. C., & Ng, I. O. (2021). Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nature Communications, 12(1), 3684. https://doi.org/10.1038/s41467-021-24010-1
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2011). Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics, 21(3), 152-161. https://doi.org/10.1097/FPC.0b013e3283385a1c
Hsieh, T. C., Elangovan, S., & Wu, J. M. (2010). Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to alpha-, gamma- and delta-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes. Anticancer Research, 30(10), 4169-4176.
Hsieh, T. C., & Wu, J. M. (2008). Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. International Journal of Oncology, 33(4), 851-859.
Huang, B. Y., Zeng, Y., Li, Y. J., Huang, X. J., Hu, N., Yao, N., Chen, M. F., Yang, Z. G., Chen, Z. S., Zhang, D. M., & Zeng, C. Q. (2017). Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. International Journal of Oncology, 51(1), 257-268. https://doi.org/10.3892/ijo.2017.4005
Husain, K., Centeno, B. A., Chen, D. T., Hingorani, S. R., Sebti, S. M., & Malafa, M. P. (2013). Vitamin E delta-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia), 6(10), 1074-1083. https://doi.org/10.1158/1940-6207.CAPR-13-0157
Husain, K., Francois, R. A., Yamauchi, T., Perez, M., Sebti, S. M., & Malafa, M. P. (2011). Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Molecular Cancer Therapeutics, 10(12), 2363-2372. https://doi.org/10.1158/1535-7163.MCT-11-0424
Husain, K., & Malafa, M. P. (2018). Role of tocotrienols in chemosensitization of cancer. In Role of nutraceuticals in cancer chemosensitization (pp. 77-97). Elsevier.
Hussein, D., & Mo, H. (2009). d-delta-Tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells. Pancreas, 38(4), e124-e136. https://doi.org/10.1097/MPA.0b013e3181a20f9c
Idriss, M., Younes, M., Abou Najem, S., Hodroj, M. H., Fakhoury, R., & Rizk, S. (2022). Gamma-tocotrienol synergistically promotes the anti-proliferative and pro-apoptotic effects of etoposide on breast cancer cell lines. Current Molecular Pharmacology, 15(7), 980-986. https://doi.org/10.2174/1874467215666220131095611
Jagadeeshan, S., Kunnumakkara, A. B., Ramachandran, I., & Nair, S. A. (2014). Anticancer activities of fruits and vegetables against gynecological cancers. In Anticancer properties of fruits and vegetables: A scientific review (pp. 131-160). World Scientific Publishing Co.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Wakelee, H., & Diehn, M. (2020). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer. Clinical Cancer Research, 26(1), 274-281. https://doi.org/10.1158/1078-0432.CCR-19-1237
Ji, X., Wang, Z., Sarkar, F. H., & Gupta, S. V. (2012). Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway. Anticancer Research, 32(7), 2647-2655.
Jones, D., Kamel-Reid, S., Bahler, D., Dong, H., Elenitoba-Johnson, K., Press, R., Quigley, N., Rothberg, P., Sabath, D., Viswanatha, D., Weck, K., & Zehnder, J. (2009). Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: A report of the Association for Molecular Pathology. The Journal of Molecular Diagnostics, 11(1), 4-11. https://doi.org/10.2353/jmoldx.2009.080095
Julianto, T., Yuen, K. H., & Noor, A. M. (2000). Improved bioavailability of vitamin E with a self emulsifying formulation. International Journal of Pharmaceutics, 200(1), 53-57. https://doi.org/10.1016/s0378-5173(00)00337-9
Kaboli, P. J., Imani, S., Jomhori, M., & Ling, K. H. (2021). Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. American Journal of Cancer Research, 11(10), 5155-5183.
Kanchi, M. M., Shanmugam, M. K., Rane, G., Sethi, G., & Kumar, A. P. (2017). Tocotrienols: The unsaturated sidekick shifting new paradigms in vitamin E therapeutics. Drug Discovery Today, 22(12), 1765-1781. https://doi.org/10.1016/j.drudis.2017.08.001
Kani, K., Momota, Y., Harada, M., Yamamura, Y., Aota, K., Yamanoi, T., Takano, H., Motegi, K., & Azuma, M. (2013). gamma-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-kappaB-regulated anti-apoptotic gene products. International Journal of Oncology, 42(1), 75-82. https://doi.org/10.3892/ijo.2012.1692
Kannampuzha, S., & Gopalakrishnan, A. V. (2023). Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role. Medical Oncology, 40(9), 264. https://doi.org/10.1007/s12032-023-02138-y
Kannappan, R., Gupta, S. C., Kim, J. H., & Aggarwal, B. B. (2012). Tocotrienols fight cancer by targeting multiple cell signaling pathways. Genes & Nutrition, 7(1), 43-52. https://doi.org/10.1007/s12263-011-0220-3
Khalaf, K., Hana, D., Chou, J. T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021). Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in Immunology, 12, 656364. https://doi.org/10.3389/fimmu.2021.656364
Khatoon, E., Banik, K., Harsha, C., Sailo, B. L., Thakur, K. K., Khwairakpam, A. D., Vikkurthi, R., Devi, T. B., Gupta, S. C., & Kunnumakkara, A. B. (2022). Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Seminars in Cancer Biology, 80, 306-339. https://doi.org/10.1016/j.semcancer.2020.06.014
Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2022). Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Science, 306, 120827. https://doi.org/10.1016/j.lfs.2022.120827
Khwairakpam, A. D., Monisha, J., Banik, K., Choudhary, H., Sharma, A., Bordoloi, D., & Kunnumakkara, A. B. (2018). Chemoresistance in brain cancer and different chemosensitization approaches. In Cancer Cell Chemoresistance and Chemosensitization; (pp. 107-127). World Scientific.
Kjaer, I. M., Kahns, S., Timm, S., Andersen, R. F., Madsen, J. S., Jakobsen, E. H., Tabor, T. P., Jakobsen, A., & Bechmann, T. (2023). Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA. Scientific Reports, 13(1), 8419. https://doi.org/10.1038/s41598-023-35362-7
Koushki, M., Amiri-Dashatan, N., Ahmadi, N., Abbaszadeh, H. A., & Rezaei-Tavirani, M. (2018). Resveratrol: A miraculous natural compound for diseases treatment. Food Science & Nutrition, 6(8), 2473-2490. https://doi.org/10.1002/fsn3.855
Krol, M., Pawlowski, K. M., Majchrzak, K., Szyszko, K., & Motyl, T. (2010). Why chemotherapy can fail? Polish Journal of Veterinary Sciences, 13(2), 399-406.
Kujawa, K. A., & Lisowska, K. M. (2015). Ovarian cancer-From biology to clinic. Advances in Hygiene and Experimental Medicine, 69, 1275-1290. https://doi.org/10.5604/17322693.1184451
Kumar, A., Hegde, M., Parama, D., & Kunnumakkara, A. B. (2022). Curcumin: The golden nutraceutical on the road to cancer prevention and therapeutics. A clinical rerspective. Critical Reviews in Oncogenesis, 27(3), 33-63. https://doi.org/10.1615/CritRevOncog.2023045587
Kunnumakkara, A. B. (2014). Anticancer properties of fruits and vegetables: A scientific review.
Kunnumakkara, A. B., Anand, P., & Aggarwal, B. B. (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters, 269(2), 199-225. https://doi.org/10.1016/j.canlet.2008.03.009
Kunnumakkara, A. B., Banik, K., Bordoloi, D., Harsha, C., Sailo, B. L., Padmavathi, G., Roy, N. K., Gupta, S. C., & Aggarwal, B. B. (2018). Googling the Guggul (Commiphora and Boswellia) for prevention of chronic diseases. Frontiers in Pharmacology, 9, 686. https://doi.org/10.3389/fphar.2018.00686
Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019). Cancer drug development: The missing links. Experimental Biology and Medicine (Maywood), 244(8), 663-689. https://doi.org/10.1177/1535370219839163
Kunnumakkara, A. B., Diagaradjane, P., Anand, P., Harikumar, K. B., Deorukhkar, A., Gelovani, J., Guha, S., Krishnan, S., & Aggarwal, B. B. (2009). Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. International Journal of Cancer, 125(9), 2187-2197. https://doi.org/10.1002/ijc.24593
Kunnumakkara, A. B., Guha, S., & Aggarwal, B. B. (2009). Curcumin and colorectal cancer: Add spice to your life. Current Colorectal Cancer Reports, 5(1), 5-14.
Kunnumakkara, A. B., Nair, A. S., Ahn, K. S., Pandey, M. K., Yi, Z., Liu, M., & Aggarwal, B. B. (2007). Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood, 109(12), 5112-5121. https://doi.org/10.1182/blood-2007-01-067256
Kunnumakkara, A. B., Padmavathi, G., & Roy, N. K. (2017). Fusion genes and cancer. World Scientific.
Kunnumakkara, A. B., Sung, B., Ravindran, J., Diagaradjane, P., Deorukhkar, A., Dey, S., Koca, C., Tong, Z., Gelovani, J. G., Guha, S., Krishnan, S., & Aggarwal, B. B. (2010). Gamma-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Research, 70(21), 8695-8705. https://doi.org/10.1158/0008-5472.CAN-10-2318
Kunnumakkara, A. B., Sung, B., Ravindran, J., Diagaradjane, P., Deorukhkar, A., Dey, S., Koca, C., Tong, Z., Gelovani, J. G., Guha, S., Krishnan, S., Aggarwal, B. B., & Guha, S. (2012). Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. International Journal of Cancer, 131(3), E292-E303.
Lan, T., Que, H., Luo, M., Zhao, X., & Wei, X. (2022). Genome editing via non-viral delivery platforms: Current progress in personalized cancer therapy. Molecular Cancer, 21(1), 71. https://doi.org/10.1186/s12943-022-01550-8
Lenzhofer, R., Ganzinger, U., Rameis, H., & Moser, K. (1983). Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. Journal of Cancer Research and Clinical Oncology, 106(2), 143-147. https://doi.org/10.1007/BF00395393
Li, H. Y., Cui, Z. M., Chen, J., Guo, X. Z., & Li, Y. Y. (2015). Pancreatic cancer: Diagnosis and treatments. Tumor Biology, 36(3), 1375-1384. https://doi.org/10.1007/s13277-015-3223-7
Li, Y., Zhang, J., Zhou, H., & Du, Z. (2022). Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review). Oncology Reports, 48(3), 156. https://doi.org/10.3892/or.2022.8368
Li, Z. W., & Dalton, W. S. (2006). Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews, 20(6), 333-342. https://doi.org/10.1016/j.blre.2005.08.003
Ling, M. T., Luk, S. U., Al-Ejeh, F., & Khanna, K. K. (2012). Tocotrienol as a potential anticancer agent. Carcinogenesis, 33(2), 233-239. https://doi.org/10.1093/carcin/bgr261
Liu, H. K., Wang, Q., Li, Y., Sun, W. G., Liu, J. R., Yang, Y. M., Xu, W. L., Sun, X. R., & Chen, B. Q. (2010). Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. Journal of Nutritional Biochemistry, 21(3), 206-213. https://doi.org/10.1016/j.jnutbio.2008.11.004
Liu, J., Lau, E. Y., Chen, J., Yong, J., Tang, K. D., Lo, J., Ng, I. O., Lee, T. K., & Ling, M. T. (2014). Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. BMC Complementary and Alternative Medicine, 14, 303. https://doi.org/10.1186/1472-6882-14-303
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020). PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death & Disease, 11(9), 797. https://doi.org/10.1038/s41419-020-02998-6
Liu, S., MericBernstam, F., Parinyanitikul, N., Wang, B., Eterovic, A. K., Zheng, X., Gagea, M., Chavez-MacGregor, M., Ueno, N. T., Lei, X., Zhou, W., Nair, L., Tripathy, D., Brown, P. H., Hortobagyi, G. N., Chen, K., Mendelsohn, J., Mills, G. B., & Gonzalez-Angulo, A. M. (2015). Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget, 6(5), 2604-2614. https://doi.org/10.18632/oncotarget.3094
Loganathan, R., Selvaduray, K. R., Nesaretnam, K., & Radhakrishnan, A. K. (2013). Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity. Cell Proliferation, 46(2), 203-213. https://doi.org/10.1111/cpr.12014
Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205(2), 275-292. https://doi.org/10.1002/path.1706
Luk, S. U., Yap, W. N., Chiu, Y. T., Lee, D. T., Ma, S., Lee, T. K., Vasireddy, R. S., Wong, Y. C., Ching, Y. P., Nelson, C, Yap, Y. L., & Ling, M. T. (2011). Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. International Journal of Cancer, 128(9), 2182-2191. https://doi.org/10.1002/ijc.25546
Ma, S. C., Zhang, J. Q., Yan, T. H., Miao, M. X., Cao, Y. M., Cao, Y. B., Cao, Y. B., Zhang, L. C., & Li, L. (2023). Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Medicine, 12(10), 11073-11096. https://doi.org/10.1002/cam4.5594
Mahipal, A., Klapman, J., Vignesh, S., Yang, C. S., Neuger, A., Chen, D. T., & Malafa, M. P. (2016). Pharmacokinetics and safety of vitamin E delta-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemotherapy and Pharmacology, 78(1), 157-165. https://doi.org/10.1007/s00280-016-3048-0
Malaviya, A., & Sylvester, P. W. (2013). Mechanisms mediating the effects of gamma-tocotrienol when used in combination with PPARgamma agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cells. International Journal of Breast Cancer, 2013, 101705. https://doi.org/10.1155/2013/101705
Malaviya, A., & Sylvester, P. W. (2014). Synergistic Antiproliferative effects of combined gamma-tocotrienol and PPAR gamma antagonist treatment are mediated through PPAR gamma-independent mechanisms in breast cancer cells. PPAR Research, 2014, 439146. https://doi.org/10.1155/2014/439146
Maniam, G., Mai, C. W., Zulkefeli, M., & Fu, J. Y. (2021). Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer. Nanomedicine (Lond), 16(5), 373-389. https://doi.org/10.2217/nnm-2020-0374
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: A brief review. Advanced Pharmaceutical Bulletin, 7(3), 339-348. https://doi.org/10.15171/apb.2017.041
Manu, K. A., Shanmugam, M. K., Ramachandran, L., Li, F., Fong, C. W., Kumar, A. P., Tan, P., & Sethi, G. (2012). First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway. Clinical Cancer Research, 18(8), 2220-2229. https://doi.org/10.1158/1078-0432.CCR-11-2470
Marin, J. J., Sanchez de Medina, F., Castaño, B., Bujanda, L., Romero, M. R., Martinez-Augustin, O., Moral-Avila, R. D., & Briz, O. (2012). Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews, 44(2), 148-172. https://doi.org/10.3109/03602532.2011.638303
Martinelli, V. (2006). Combination therapy. Neurological Sciences, 27(Suppl 5), S350-S354. https://doi.org/10.1007/s10072-006-0692-x
Marusyk, A., Janiszewska, M., & Polyak, K. (2020). Intratumor heterogeneity: The Rsetta Stone of therapy resistance. Cancer Cell, 37(4), 471-484. https://doi.org/10.1016/j.ccell.2020.03.007
Maruthanila, V. L., Elancheran, R., Kunnumakkara, A. B., Kabilan, S., & Kotoky, J. (2017). Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer, 24(2), 191-219. https://doi.org/10.1007/s12282-016-0732-1
McAnally, J. A., Gupta, J., Sodhani, S., Bravo, L., & Mo, H. (2007). Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Experimental Biology and Medicine (Maywood), 232(4), 523-531.
Meganathan, P., Jabir, R. S., Fuang, H. G., Bhoo-Pathy, N., Choudhury, R. B., Taib, N. A., Nesaretnam, K., & Chik, Z. (2015). A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing tocotrienol-rich fraction in healthy human subjects. Scientific Reports, 5, 13550. https://doi.org/10.1038/srep13550
Mezencev, R., Matyunina, L. V., Wagner, G. T., & McDonald, J. F. (2016). Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Therapy, 23(12), 446-453. https://doi.org/10.1038/cgt.2016.71
Mohammad, I. S., He, W., & Yin, L. (2018). Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomedicine & Pharmacotherapy, 100, 335-348. https://doi.org/10.1016/j.biopha.2018.02.038
Monisha, J., Jaiswal, A., Banik, K., Choudhary, H., Singh, A. K., Bordoloi, D., & Kunnumakkara, A. B. (2018). Cancer cell chemoresistance: A prime obstacle in cancer therapy. Cancer Cell Chemoresistance and Chemosensitization; World Scientific: Singapore, 15-49.
Monisha, J., Padmavathi, G., Bakliwal, V., Katre, N., Padikkala, J., & Kunnumakkara, A. B. (2015). Cancer preventive and therapeutic properties of fruits and vegetables against commonly occurring cancers in humans. In Anticancer properties of fruits and vegetables: A scientific review (pp. 337-366). World Scientific.
Monisha, J., Padmavathi, G., Roy, N. K., Deka, A., Bordoloi, D., Anip, A., & Kunnumakkara, A. B. (2016). NF-kappaB blockers gifted by mother nature: Prospectives in cancer cell Chemosensitization. Current Pharmaceutical Design, 22(27), 4173-4200. https://doi.org/10.2174/1381612822666160609110231
Muralimanoharan, S. B., Kunnumakkara, A. B., Shylesh, B., Kulkarni, K. H., Haiyan, X., Ming, H., Aggarwal, B. B., Rita, G., & Kumar, A. P. (2009). Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate, 69(5), 494-504. https://doi.org/10.1002/pros.20899
Nakashima, K., Virgona, N., Miyazawa, M., Watanabe, T., & Yano, T. (2010). The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells. Phytotherapy Research, 24(9), 1317-1321. https://doi.org/10.1002/ptr.3107
Namazi, H., Kulish, V. V., Delaviz, F., & Delaviz, A. (2015). Diagnosis of skin cancer by correlation and complexity analyses of damaged DNA. Oncotarget, 6(40), 42623-42631. https://doi.org/10.18632/oncotarget.6003
Nasr, M., Nafee, N., Saad, H., & Kazem, A. (2014). Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. European Journal of Pharmaceuticals and Biopharmaceuticals, 88(1), 216-225. https://doi.org/10.1016/j.ejpb.2014.04.016
Nesaretnam, K., Selvaduray, K. R., Abdul Razak, G., Veerasenan, S. D., & Gomez, P. A. (2010). Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: A pilot clinical trial. Breast Cancer Research, 12(5), R81. https://doi.org/10.1186/bcr2726
Ohnmacht, S., West, R., Simionescu, R., & Atkinson, J. (2008). Assignment of the 1H and 13C NMR of tocotrienols. Magnetic Resonance in Chemistry, 46(3), 287-294. https://doi.org/10.1002/mrc.2176
Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., Cheng, M. H., Subramanian, A., Mu, D., Powers, S., Crowley, D., Bronson, R. T., Whittaker, C. A., Bhutkar, A., Lippard, S. J., Golub, T., Thomale, J., Jacks, T., & Sweet-Cordero, E. A. (2010). Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes & Development, 24(8), 837-852. https://doi.org/10.1101/gad.1897010
Padmavathi, G., Monisha, J., Banik, K., Thakur, K. K., Choudhary, H., Bordoloi, D., & Kunnumakkara, A. B. (2018). Different chemosensitization approaches to overcome chemoresistance in prostate cancer. In Cancer cell chemoresistance and chemosensitization (pp. 583-613). World Scientific.
Padmavathi, G., Rathnakaram, S. R., Monisha, J., Bordoloi, D., Roy, N. K., & Kunnumakkara, A. B. (2015). Potential of butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine, 22(13), 1163-1171. https://doi.org/10.1016/j.phymed.2015.08.015
Pal, B., Bayat-Mokhtari, R., Li, H., Bhuyan, R., Talukdar, J., Sandhya, S., Sarma, A., Tasabehji, W., Bhuyan, S., Gayan, S., & Kataki, A. C. (2016). Stem cell altruism may serve as a novel drug resistance mechanism in oral cancer. Cancer Research, 76(14_Supplement), 251.
Palmieri, B., Gozzi, G., & Palmieri, G. (1995). Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids. International Journal of Dermatology, 34(7), 506-509. https://doi.org/10.1111/j.1365-4362.1995.tb00628.x
Parajuli, P., Tiwari, R. V., & Sylvester, P. W. (2015a). Anti-proliferative effects of gamma-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells. Cell Proliferation, 48(4), 421-435. https://doi.org/10.1111/cpr.12196
Parajuli, P., Tiwari, R. V., & Sylvester, P. W. (2015b). Anticancer effects of gamma-tocotrienol are associated with a suppression in aerobic glycolysis. Biological and Pharmaceutical Bulletin, 38(9), 1352-1360. https://doi.org/10.1248/bpb.b15-00306
Pavlasova, G., & Mraz, M. (2020). The regulation and function of CD20: An “enigma” of B-cell biology and targeted therapy. Haematologica, 105(6), 1494-1506. https://doi.org/10.3324/haematol.2019.243543
Pereira, I. C., Mascarenhas, I. F., Capetini, V. C., Ferreira, P. M. P., Rogero, M. M., & Torres-Leal, F. L. (2022). Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. Critical Reviews in Oncology/Hematology, 179, 103796. https://doi.org/10.1016/j.critrevonc.2022.103796
Peterson, C., Denlinger, N., & Yang, Y. (2022). Recent advances and challenges in cancer immunotherapy. Cancers (Basel), 14(16), 3972. https://doi.org/10.3390/cancers14163972
Pizato, N., Kiffer, L., Luzete, B. C., Assumpcao, J. A. F., Correa, L. H., Melo, H. A. B., Sant'Ana, L. P., Ito, M. K., & Magalhaes, K. G. (2019). Omega 3-DHA and Delta-Tocotrienol modulate lipid droplet biogenesis and lipophagy in breast cancer cells: The impact in cancer aggressiveness. Nutrients, 11(6), 1199 https://doi.org/10.3390/nu11061199
Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2016). gamma-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. British Journal of Cancer, 115(7), 814-824. https://doi.org/10.1038/bjc.2016.257
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., Deschler, D. G., Varvares, M. A., Mylvaganam, R., Rozenblatt-Rosen, O., Rocco, J. W., Faquin, W. C., Lin, D. T., Regev, A., & Bernstein, B. E. (2017). Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell, 171(7), 1611-1624.e1624. https://doi.org/10.1016/j.cell.2017.10.044
Rajendran, P., Li, F., Manu, K. A., Shanmugam, M. K., Loo, S. Y., Kumar, A. P., & Sethi, G. (2011). gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: Potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. British Journal of Pharmacology, 163(2), 283-298. https://doi.org/10.1111/j.1476-5381.2010.01187.x
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021). Battling Chemoresistance in cancer: Root causes and strategies to uproot them. International Journal of Molecular Sciences, 22(17), 9451. https://doi.org/10.3390/ijms22179451
Raunkilde, L., Hansen, T. F., Havelund, B. M., Thomsen, C. B., Rafaelsen, S. R., Lindebjerg, J., & Jensen, L. H. (2023). Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study. Acta Oncologica, 62(9), 1066-1075. https://doi.org/10.1080/0284186X.2023.2249225
Raviadaran, R., Ng, M. H., Chandran, D., Ooi, K. K., & Manickam, S. (2021). Stable W/O/W multiple nanoemulsion encapsulating natural tocotrienols and caffeic acid with cisplatin synergistically treated cancer cell lines (A549 and HEP G2) and reduced toxicity on normal cell line (HEK 293). Materials Science and Engineering C: Materials for Biological Applications, 121, 111808. https://doi.org/10.1016/j.msec.2020.111808
Recondo, G., Che, J., Janne, P. A., & Awad, M. M. (2020). Targeting MET dysregulation in cancer. Cancer Discovery, 10(7), 922-934. https://doi.org/10.1158/2159-8290.CD-19-1446
Rees, D. C., Johnson, E., & Lewinson, O. (2009). ABC transporters: The power to change. Nature Reviews Molecular Cell Biology, 10(3), 218-227. https://doi.org/10.1038/nrm2646
Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 5(3), 172-183. https://doi.org/10.1038/nrc1567
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105-111. https://doi.org/10.1038/35102167
Rowley, J. D. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243(5405), 290-293. https://doi.org/10.1038/243290a0
Sailo, B. L., Banik, K., Padmavathi, G., Javadi, M., Bordoloi, D., & Kunnumakkara, A. B. (2018). Tocotrienols: The promising analogues of vitamin E for cancer therapeutics. Pharmacological Research, 130, 259-272. https://doi.org/10.1016/j.phrs.2018.02.017
Sajeev, A., Hegde, M., Girisa, S., Devanarayanan, T. N., Alqahtani, M. S., Abbas, M., Sil, S. K., Sethi, G., Chen, J. T., & Kunnumakkara, A. B. (2022). Oroxylin A: A promising flavonoid for prevention and treatment of chronic diseases. Biomolecules, 12(9), 1185. https://doi.org/10.3390/biom12091185
Sajid, A., Rahman, H., & Ambudkar, S. V. (2023). Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nature Reviews Cancer, 23(11), 762-779. https://doi.org/10.1038/s41568-023-00612-3
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103-119. https://doi.org/10.1517/14728222.2011.645805
Saraswathy, M., & Gong, S. (2013). Different strategies to overcome multidrug resistance in cancer. Biotechnology Advances, 31(8), 1397-1407. https://doi.org/10.1016/j.biotechadv.2013.06.004
Sato, C., Kaneko, S., Sato, A., Virgona, N., Namiki, K., & Yano, T. (2017). Combination effect of delta-Tocotrienol and gamma-tocopherol on prostate cancer cell growth. Journal of Nutritional Science and Vitaminology (Tokyo), 63(5), 349-354. https://doi.org/10.3177/jnsv.63.349
Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmacology, 2012, 195727. https://doi.org/10.5402/2012/195727
Selvaduray, K. R., Radhakrishnan, A. K., Kutty, M. K., & Nesaretnam, K. (2010). Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. Journal of Interferon & Cytokine Research, 30(12), 909-916. https://doi.org/10.1089/jir.2010.0021
Selvaduray, K. R., Radhakrishnan, A. K., Kutty, M. K., & Nesaretnam, K. (2012). Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells. Genes & Nutrition, 7(1), 53-61. https://doi.org/10.1007/s12263-011-0223-0
Sen, C. K., Khanna, S., Rink, C., & Roy, S. (2007). Tocotrienols: The emerging face of natural vitamin E. Vitamins and Hormones, 76, 203-261. https://doi.org/10.1016/S0083-6729(07)76008-9
Sen, C. K., Khanna, S., & Roy, S. (2007). Tocotrienols in health and disease: The other half of the natural vitamin E family. Molecular Aspects of Medicine, 28(5-6), 692-728. https://doi.org/10.1016/j.mam.2007.03.001
Shabnam, B., Padmavathi, G., Banik, K., Girisa, S., Monisha, J., Sethi, G., Fan, L., Wang, L., Mao, X., & Kunnumakkara, A. B. (2018). Sorcin a potential molecular target for cancer therapy. Translational Oncology, 11(6), 1379-1389. https://doi.org/10.1016/j.tranon.2018.08.015
Shahidi, F., & de Camargo, A. C. (2016). Tocopherols and Tocotrienols in common and emerging dietary sources: Occurrence, applications, and health benefits. International Journal of Molecular Sciences, 17(10), 1745. https://doi.org/10.3390/ijms17101745
Sharifi-Rad, J., Quispe, C., Imran, M., Rauf, A., Nadeem, M., Gondal, T. A., Ahmad, B., Atif, M., Mubarak, M. S., Sytar, O., Zhilina, O. M., Garsiya, E. R., Smeriglio, A., Trombetta, D., Pons, D. G., Martorell, M., Cardoso, S. M., Razis, A. F. A., Sunusi, U., & Calina, D. (2021). Genistein: An integrative overview of its mode of action, pharmacological properties, and health benefits. Oxidative Medicine and Cellular Longevity, 2021, 3268136. https://doi.org/10.1155/2021/3268136
Shirode, A. B., & Sylvester, P. W. (2010). Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomedicine & Pharmacotherapy, 64(5), 327-332. https://doi.org/10.1016/j.biopha.2009.09.018
Shun, M. C., Yu, W., Gapor, A., Parsons, R., Atkinson, J., Sanders, B. G., & Kline, K. (2004). Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutrition and Cancer, 48(1), 95-105. https://doi.org/10.1207/s15327914nc4801_13
Singh, Y. P., Girisa, S., Banik, K., Ghosh, S., Swathi, P., Deka, M., Padmavathi, G., Kotoky, J., Sethi, G., Fan, L., & Fan, L. (2019). Potential application of zerumbone in the prevention and therapy of chronic human diseases. Journal of Functional Foods, 53, 248-258.
Sirithunyalug, B., Saenjum, C., Charumanee, S., Sivamaruthi, B. S., Chaiyasut, C., Sirithunyalug, J., & Tipduangta, P. (2018). Development of colorectal-targeted dietary supplement tablets containing natural purple rice bran oil as a colorectal chemopreventive. Nutrients, 10(4), 444. https://doi.org/10.3390/nu10040444
Srivastava, J. K., & Gupta, S. (2006). Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochemical and Biophysical Research Communications., 346(2), 447-453. https://doi.org/10.1016/j.bbrc.2006.05.147
Springett, G. M., Husain, K., Neuger, A., Centeno, B., Chen, D. T., Hutchinson, T. Z., Lush, R. M., Sebti, S., & Malafa, M. P. (2015). A phase I safety, pharmacokinetic, and pharmacodynamic presurgical trial of vitamin E delta-tocotrienol in patients with pancreatic ductal neoplasia. EBioMedicine, 2(12), 1987-1995. https://doi.org/10.1016/j.ebiom.2015.11.025
Steuber, N., Vo, K., Wadhwa, R., Birch, J., Iacoban, P., Chavez, P., & Elbayoumi, T. A. (2016). Tocotrienol nanoemulsion platform of curcumin elicit elevated apoptosis and augmentation of anticancer efficacy against breast and ovarian carcinomas. International Journal of Molecular Sciences, 17(11), 1792. https://doi.org/10.3390/ijms17111792
Sun, X. X., & Yu, Q. (2015). Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica, 36(10), 1219-1227. https://doi.org/10.1038/aps.2015.92
Sylvester, P. W. (2012). Synergistic anticancer effects of combined gamma-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment. Genes & Nutrition, 7(1), 63-74. https://doi.org/10.1007/s12263-011-0225-y
Sylvester, P. W., Shah, S. J., & Samant, G. V. (2005). Intracellular signaling mechanisms mediating the antiproliferative and apoptotic effects of gamma-tocotrienol in neoplastic mammary epithelial cells. Journal of Plant Physiology, 162(7), 803-810. https://doi.org/10.1016/j.jplph.2005.04.014
Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5(3), 219-234. https://doi.org/10.1038/nrd1984
Tang, K. D., Liu, J., Russell, P. J., Clements, J. A., & Ling, M. T. (2019). Gamma-Tocotrienol induces apoptosis in prostate cancer cells by targeting the Ang-1/Tie-2 signalling pathway. International Journal of Molecular Sciences, 20(5), 1164. https://doi.org/10.3390/ijms20051164
Thakur, K. K., Bordoloi, D., & Kunnumakkara, A. B. (2018). Alarming burden of triple-negative breast cancer in India. Clinical Breast Cancer, 18(3), e393-e399. https://doi.org/10.1016/j.clbc.2017.07.013
Thakur, K. K., Kumar, A., Banik, K., Verma, E., Khatoon, E., Harsha, C., Sethi, G., Gupta, S. C., & Kunnumakkara, A. B. (2021). Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis. Journal of Cellular Physiology, 236(12), 7938-7965. https://doi.org/10.1002/jcp.30463
Tham, S. Y., Loh, H. S., Mai, C. W., & Fu, J. Y. (2019). Tocotrienols modulate a life or death decision in cancers. International Journal of Molecular Sciences, 20(2). https://doi.org/10.3390/ijms20020372
Thomsen, C. B., Andersen, R. F., Steffensen, K. D., Adimi, P., & Jakobsen, A. (2019). Delta tocotrienol in recurrent ovarian cancer. A phase II trial. Pharmacological Research, 141, 392-396. https://doi.org/10.1016/j.phrs.2019.01.017
Tiek, D., & Cheng, S. Y. (2022). DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resistance, 5(2), 368-379. https://doi.org/10.20517/cdr.2021.148
Tiwari, R. V., Parajuli, P., & Sylvester, P. W. (2015). Synergistic anticancer effects of combined gamma-tocotrienol and oridonin treatment is associated with the induction of autophagy. Molecular and Cellular Biochemistry, 408(1-2), 123-137. https://doi.org/10.1007/s11010-015-2488-x
Townsend, D. M., & Tew, K. D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369-7375. https://doi.org/10.1038/sj.onc.1206940
Tran, A. T., Ramalinga, M., Kedir, H., Clarke, R., & Kumar, D. (2015). Autophagy inhibitor 3-methyladenine potentiates apoptosis induced by dietary tocotrienols in breast cancer cells. European Journal of Nutrition, 54(2), 265-272. https://doi.org/10.1007/s00394-014-0707-y
Trujillo, M., Kharbanda, A., Corley, C., Simmons, P., & Allen, A. R. (2021). Tocotrienols as an anti-breast cancer agent. Antioxidants (Basel), 10(9). https://doi.org/10.3390/antiox10091383
Tuerdi, G., Ichinomiya, S., Sato, H., Siddig, S., Suwa, E., Iwata, H., Yano, T., & Ueno, K. (2013). Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells. Cancer Letters, 339(1), 116-127. https://doi.org/10.1016/j.canlet.2013.07.015
Tupal, A., Sabzichi, M., Bazzaz, R., Fathi Maroufi, N., Mohammadi, M., Pirouzpanah, S. M., & Ramezani, F. (2020). Application of a-Tocotrienol-loaded biocompatible precirol in attenuation of doxorubicin dose-dependent behavior in HUH-7 hepatocarcinoma cell line. Nutrition and Cancer, 72(4), 653-661. https://doi.org/10.1080/01635581.2019.1650191
Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Vinals, F., & Capella, G. (2010). Recent advances in cancer therapy: An overview. Current Pharmaceutical Design, 16(1), 3-10. https://doi.org/10.2174/138161210789941847
Verma, E., Kumar, A., Daimary, U. D., Parama, D., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2021). Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review. Journal of Functional Foods, 86, 104660.
Wali, V. B., Bachawal, S. V., & Sylvester, P. W. (2009). Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Experimental Biology and Medicine (Maywood), 234(6), 639-650. https://doi.org/10.3181/0810-RM-300
Wali, V. B., & Sylvester, P. W. (2007). Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids, 42(12), 1113-1123. https://doi.org/10.1007/s11745-007-3102-0
Weng-Yew, W., Selvaduray, K. R., Ming, C. H., & Nesaretnam, K. (2009). Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutrition and Cancer, 61(3), 367-373. https://doi.org/10.1080/01635580802582736
Wirsching, H. G., Galanis, E., & Weller, M. (2016). Glioblastoma. Handbook of Clinical Neurology, 134, 381-397. https://doi.org/10.1016/B978-0-12-802997-8.00023-2
Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., Zhang, Y., Zhao, W., Zhou, F., Li, W., Zhang, J., Zhang, X., Qiao, M., Gao, G., Chen, S., Chen, X., Li, X., Hou, L., Wu, C., & Zhou, C. (2021). Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nature Communications, 12(1), 2540. https://doi.org/10.1038/s41467-021-22801-0
Xiong, A., Yu, W., Liu, Y., Sanders, B. G., & Kline, K. (2016). Elimination of ALDH+ breast tumor initiating cells by docosahexanoic acid and/or gamma tocotrienol through SHP-1 inhibition of Stat3 signaling. Molecular Carcinogenesis, 55(5), 420-430. https://doi.org/10.1002/mc.22291
Yang, C. S., Luo, P., Zeng, Z., Wang, H., Malafa, M., & Suh, N. (2020). Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols. Molecular Carcinogenesis, 59(4), 365-389. https://doi.org/10.1002/mc.23160
Yang, Z., Xiao, H., Jin, H., Koo, P. T., Tsang, D. J., & Yang, C. S. (2010). Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. International Journal of Cancer, 126(4), 852-863. https://doi.org/10.1002/ijc.24766
Yap, S. P., Yuen, K. H., & Lim, A. B. (2003). Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. Journal of Pharmacy and Pharmacology, 55(1), 53-58. https://doi.org/10.1111/j.2042-7158.2003.tb02433.x
Yap, W. N., Chang, P. N., Han, H. Y., Lee, D. T., Ling, M. T., Wong, Y. C., & Yap, Y. L. (2008). Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. British Journal of Cancer, 99(11), 1832-1841. https://doi.org/10.1038/sj.bjc.6604763
Yap, W. N., Zaiden, N., Luk, S. Y., Lee, D. T., Ling, M. T., Wong, Y. C., & Yap, Y. L. (2010). In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology, 85(4), 248-258. https://doi.org/10.1159/000278205
Yap, W. N., Zaiden, N., Tan, Y. L., Ngoh, C. P., Zhang, X. W., Wong, Y. C., Ling, M. T., & Yap, Y. L. (2010). Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Letters, 291(2), 187-199. https://doi.org/10.1016/j.canlet.2009.10.012
Ye, C., Zhao, W., Li, M., Zhuang, J., Yan, X., Lu, Q., Chang, C., Huang, X., Zhou, J., Xie, B., Zhang, Z., Yao, X., Yan, J., & Guo, H. (2015). delta-Tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway. PLoS One, 10(4), e0122712. https://doi.org/10.1371/journal.pone.0122712
Yeganehjoo, H., DeBose-Boyd, R., McFarlin, B. K., & Mo, H. (2017). Synergistic impact of d-delta-tocotrienol and geranylgeraniol on the growth and HMG CoA reductase of human DU145 prostate carcinoma cells. Nutrition and Cancer, 69(4), 682-691. https://doi.org/10.1080/01635581.2017.1299876
Yu, K., Hu, Y., Wu, F., Guo, Q., Qian, Z., Hu, W., Chen, J., Wang, K., Fan, X., Wu, X., Rasko, J. E., Fan, X., Iavarone, A., Jiang, T., Tang, F., & Su, X. D. (2020). Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. National Science Review, 7(8), 1306-1318. https://doi.org/10.1093/nsr/nwaa099
Yusof, K. M., Makpol, S., Fen, L. S., Jamal, R., & Wan Ngah, W. Z. (2019). Suppression of colorectal cancer cell growth by combined treatment of 6-gingerol and gamma-tocotrienol via alteration of multiple signalling pathways. Journal of Natural Medicines, 73(4), 745-760. https://doi.org/10.1007/s11418-019-01323-6
Yusof, K. M., Makpol, S., Jamal, R., Harun, R., Mokhtar, N., & Ngah, W. Z. (2015). gamma-Tocotrienol and 6-gingerol in combination synergistically induce cytotoxicity and apoptosis in HT-29 and SW837 human colorectal cancer cells. Molecules, 20(6), 10280-10297. https://doi.org/10.3390/molecules200610280
Zhang, A., Miao, K., Sun, H., & Deng, C. X. (2022). Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. International Journal of Biological Sciences, 18(7), 3019-3033. https://doi.org/10.7150/ijbs.72534
Zhang, J. S., Li, D. M., Ma, Y., He, N., Gu, Q., Wang, F. S., Jiang, S. Q., Chen, B. Q., & Liu, J. R. (2013). gamma-Tocotrienol induces paraptosis-like cell death in human colon carcinoma SW620 cells. PLoS One, 8(2), e57779. https://doi.org/10.1371/journal.pone.0057779
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., Peet, G. W., Zhong, G., Lu, S., Zhu, W., Mao, Y., Xiao, M., Bergmann, M., Hu, X., Kerkar, S. P., & Zhang, Z. (2019). Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell, 179(4), 829-845 e820. https://doi.org/10.1016/j.cell.2019.10.003
Zhao, J. (2016). Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacology & Therapeutics, 160, 145-158. https://doi.org/10.1016/j.pharmthera.2016.02.008
Zheng, C., Zheng, L., Yoo, J. K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., Liu, Z., Dong, M., Hu, X., Ouyang, W., Peng, J., & Zhang, Z. (2017). Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell, 169(7), 1342-1356.e1316. https://doi.org/10.1016/j.cell.2017.05.035
Zhou, S., Huang, Y. E., Liu, H., Zhou, X., Yuan, M., Hou, F., Wang, L., & Jiang, W. (2021). Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks. Molecular Therapy - Nucleic Acids, 23, 682-690. https://doi.org/10.1016/j.omtn.2020.12.018